Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2011-3-22
pubmed:abstractText
We enumerated programmed death 1 (PD-1)-positive follicular helper T cells, a potentially important regulator of immune response, in the tumor microenvironment of a series of 91 newly diagnosed follicular lymphomas managed at a single institution. Clinical data were obtained for sex, age, Follicular Lymphoma International Prognostic Index (FLIPI) risk group, presence of bulky disease, presence of B symptoms, and overall survival. Immunohistochemical staining for PD-1 was performed on tissue microarray sections, and the mean number of follicular PD-1-positive cells per 9 high-power fields (1000×, 3 follicles with 3 fields per follicle) was quantified. B-cell CLL/lymphoma 2 (BCL-2) expression, CD68(+) extrafollicular lymphoma-associated macrophages, and forkhead box P3 (FOXP3)+ regulatory T cells were evaluated as reported previously. Ninety-one patients were evaluated, with a median age at diagnosis of 58 years and median survival of 11.6 years. PD-1-positive cells correlated with the number of FOXP3+ regulatory T cells (P = .01). On multivariate analysis, independent poor prognostic factors were age 55 years or greater (hazard ratio, 2.77; 95% confidence interval, 1.34-5.73; P = .006), bulky disease (hazard ratio, 2.27; 95% confidence interval, 1.03-5.00; P = .04), CD68(+) extrafollicular lymphoma-associated macrophages greater than 16.8 cells/high-power field (hazard ratio, 2.15; 95% confidence interval, 1.14-4.06; P = .02), and PD-1-positive cells greater than 35.6 cells/high-power field (hazard ratio, 1.98; 95% confidence interval, 1.09-3.60; P = .03). These factors allowed construction of a risk score defining 3 distinct prognostic groups with 10-year overall survival of 85%, 60%, and 15%. PD-1-positive follicular helper T cells and CD68(+) extrafollicular lymphoma-associated macrophages appear to predict overall survival in follicular lymphoma, and our findings support strategies aimed at modulating their function in follicular lymphoma. Future studies, performed prospectively on uniformly treated patient cohorts, should be performed to validate these findings.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1532-8392
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
552-7
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:21237493-Adult, pubmed-meshheading:21237493-Aged, pubmed-meshheading:21237493-Aged, 80 and over, pubmed-meshheading:21237493-Antigens, CD, pubmed-meshheading:21237493-Antigens, Differentiation, Myelomonocytic, pubmed-meshheading:21237493-Apoptosis Regulatory Proteins, pubmed-meshheading:21237493-Female, pubmed-meshheading:21237493-Humans, pubmed-meshheading:21237493-Immunohistochemistry, pubmed-meshheading:21237493-Kaplan-Meier Estimate, pubmed-meshheading:21237493-Lymphocytes, Tumor-Infiltrating, pubmed-meshheading:21237493-Lymphoma, Follicular, pubmed-meshheading:21237493-Macrophages, pubmed-meshheading:21237493-Male, pubmed-meshheading:21237493-Middle Aged, pubmed-meshheading:21237493-Prognosis, pubmed-meshheading:21237493-Programmed Cell Death 1 Receptor, pubmed-meshheading:21237493-Proportional Hazards Models, pubmed-meshheading:21237493-Risk Factors, pubmed-meshheading:21237493-T-Lymphocytes, Helper-Inducer, pubmed-meshheading:21237493-T-Lymphocytes, Regulatory, pubmed-meshheading:21237493-Tissue Array Analysis, pubmed-meshheading:21237493-Tumor Markers, Biological, pubmed-meshheading:21237493-Tumor Microenvironment, pubmed-meshheading:21237493-Young Adult
pubmed:year
2011
pubmed:articleTitle
Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.
pubmed:affiliation
Clinical Pathology, Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH 44195, USA. richenb@ccf.org
pubmed:publicationType
Journal Article